Xellia Pharmaceuticals USA LLCSeptember 29, 2023

FDA 483 - Xellia Pharmaceuticals USA LLC - September 29, 2023

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xellia Pharmaceuticals USA LLC

Record Details

Xellia Pharmaceuticals USA LLC in Bedford, OH, a manufacturer of sterile drug products, received a Form 483 with two observations. The inspection revealed significant deficiencies in aseptic process validation, including unrepresentative media fills and inadequate smoke studies for Vancomycin production. Additionally, the firm failed to conduct thorough investigations into unexplained discrepancies, such as the source of a metal shard found in a Vancomycin batch.

Company: Xellia Pharmaceuticals USA LLC
Inspection Date: September 29, 2023
Product Type: Drugs
Office: Cincinnati District Office
People: Nicholas J. Presto
Alan M. Barker (Investigator)

Open in Dashboard

ID · 93d44f5f-72c1-46b2-a9d2-b59938687b28